Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NGM Biopharmaceuticals Inc.

www.ngmbio.com

Latest From NGM Biopharmaceuticals Inc.

NASH Companies Take The Stage At AASLD

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

Research and Development Strategies Clinical Trials

Hepalink-Backed HighTide Bets On NASH For Global Markets

Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.


China Liver & Hepatic

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Hepatic (Liver)
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NGM Biopharmaceuticals Inc.
  • Senior Management
  • David Woodhouse, CEO & Interim CFO
    Jin-Long Chen, PhD, CSO
    Aetna Wun Trombley, PhD, Pres. & COO
    Hsiao D Lieu, MD, SVP, CMO
  • Contact Info
  • NGM Biopharmaceuticals Inc.
    Phone: (650) 243-5555
    333 Oyster Point Blvd.
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register